Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278479 · ClinicalTrials.gov registry record · Phase 1
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
A Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma, sponsored by Molecular Partners.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
- 1
- Study location
NCT07278479: Recruiting Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma, sponsored by Molecular Partners.
NCT07278479 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma that is actively recruiting participants, run by Molecular Partners. The registered enrollment target is 138 participants, below the 283-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07278479, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma, is actively recruiting participants, sponsored by Molecular Partners.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Primary Outcome
Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Conditions Studied
Interventions
- DRUG [212Pb]Pb-MP0712
- OTHER [203Pb]Pb-MP0712
Study Locations (1)
Nebraska
- Nebraska Cancer Specialists - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2026-01 |
| Est. Completion | 2032-09 |
| Phase | Phase 1 |
What NCT07278479 shows while recruiting
NCT07278479 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (51% lower).
The record links to 7 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 2 interventions - of which [212Pb]Pb-MP0712 is the first listed.
NCT07278479 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT07278479 about?
NCT07278479 is a clinical study titled "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
What is the current status of trial NCT07278479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2026-01. Estimated completion is 2032-09.
What conditions does trial NCT07278479 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma, Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Gastroenteropancreatic NEC (GEP NEC).
What interventions are being tested in trial NCT07278479?
The interventions under investigation include: [212Pb]Pb-MP0712 (DRUG), [203Pb]Pb-MP0712 (OTHER).
Who is sponsoring clinical trial NCT07278479?
This trial is sponsored by Molecular Partners, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278479 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07278479's enrollment target sits among peer trials
138 8th of 12 higher than 5 of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia